InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,296.80
(
0.43%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.42
(
1.12%
)
Bitcoin
61,561.23
(
1.23%
)
Post# of 252409
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4594
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: jbog post# 217282

Wednesday, 02/14/2018 12:23:55 PM

Wednesday, February 14, 2018 12:23:55 PM

Post# of 252409

Nektar also retains the freedom to develop NKTR-214 with other third-party assets, as long as the mechanism of action doesn't overlap with Bristol-Myers' drugs



I would think most combinations would require a PD-1 backbone, so does NKTR retain the right to develop 214 with opdivo plus any other non-PD-1/non-CTLA-4 from a 3rd party? e.g. could they strike a deal w INCY for 214 plus epacadustat plus opdivo?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up